Product Information
CARBIDOPA-LEVO ER 50-200 TAB is a generic product labeled by Sun Pharmaceutical Industries Inc., priced at $0.1735 per EA under NDC 62756045788. Its NADAC has been published 665 times since Nov 28, 2013.
FDA first approved this application on Aug 23, 2007.
Strength
50; 200 mg/1; mg/1
Manufacturer
Sun Pharmaceutical Industries Inc.NDC
62756045788
Classification
Generic
Dosage Form
TABLET, EXTENDED RELEASE
Route
ORAL
Effective Date
8/19/2026
Active Ingredients
CARBIDOPA; LEVODOPAApproval Type
Generic (ANDA)
FDA Application
ANDA077828FDA Approved
8/23/2007
On Market Since
8/23/2007
Pharmacological Classes
Price Statistics
The NADAC for CARBIDOPA-LEVO ER 50-200 TAB has been published 665 times since Nov 28, 2013, and over the history we have for it it has declined 59.1%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.1735 per EA |
|---|---|
| All-time high | $0.6666 (May 13, 2015) |
| All-time low | $0.1551 (May 22, 2024) |
| 52-week high | $0.2057 |
| 52-week low | $0.1676 |
| Median price | $0.3709 |
| Average price | $0.3472 |
| Largest weekly change | +52.4% (Jun 19, 2024) |
| Weeks tracked | 665 |
| Tracking since | Nov 28, 2013 |
1W
N/A
1M
N/A
3M
-1.2%
6M
-3.6%
1Y
-15.7%
3Y
-25.9%
5Y
-44.2%
All
-59.1%
Last surveyed Aug 19, 2026 — this NDC no longer appears in the current weekly NADAC file.
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the CARBIDOPA AND LEVODOPA market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Sun Pharmaceutical Industries Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
CARBIDOPA AND LEVODOPA market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Aromatic Amino Acid class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of CARBIDOPA-LEVO ER 50-200 TAB?
The current National Average Drug Acquisition Cost (NADAC) for CARBIDOPA-LEVO ER 50-200 TAB, manufactured by Sun Pharmaceutical Industries Inc., is $0.1735 per EA (NDC 62756045788), effective Aug 19, 2026.
How has the price of CARBIDOPA-LEVO ER 50-200 TAB changed over time?
Over the history we have for it, the NADAC for CARBIDOPA-LEVO ER 50-200 TAB has declined 59.1%. It has been tracked across 665 weekly CMS publications since Nov 28, 2013.
What are the highest and lowest recorded NADAC prices for CARBIDOPA-LEVO ER 50-200 TAB?
Since Nov 28, 2013, the NADAC for CARBIDOPA-LEVO ER 50-200 TAB has ranged from a low of $0.1551 (May 22, 2024) to a high of $0.6666 (May 13, 2015), with a median of $0.3709 per EA.
Are there cheaper alternatives to CARBIDOPA-LEVO ER 50-200 TAB?
No other NADAC-published product currently shares the active ingredient and strength of CARBIDOPA-LEVO ER 50-200 TAB in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures CARBIDOPA-LEVO ER 50-200 TAB?
CARBIDOPA-LEVO ER 50-200 TAB (NDC 62756045788) is labeled by Sun Pharmaceutical Industries Inc., and CMS classifies it as a generic product.